Latest news

• Roche gets wider approval for haemophilia drug Hemlibra

  Hemlibra (eculizumab) was cleared for use in patients with inhibitors last year, and is now the only FDA-approved drug for both sets of patients. ... Roche says that Hemlibra is the first drug to show an improvement over standard haemophilia A treatment,

• Bayer roll-out of haemophilia drug Jivi gathers pace

  Meanwhile, the imminent regulatory verdict in the US for Roche’s Hemlibra (emicizumab) in haemophilia A patients without inhibitors to factor VIII, which could dramatically broaden the number of patients eligible

• Roche highlights Hemlibra data as key FDA date approaches

  It also says 98% of patients in this trial preferred Hemlibra over factor VIII prophylaxis. ... Horning added: “Given the challenges many people face managing their haemophilia, we believe Hemlibra could make a meaningful difference.”.

• Immunology keeps Shire figures solid as Takeda takeover nears

  However, Shire’s drugs for haemophilia patients with inhibitors such as Feiba came under competitive pressure from the likes of Roche’s recently-approved Hemlibra (emicizumab), falling 6%.

• NHS England says yes to Roche's Hemlibra

  But stalls on funding for Actelion's Uptravi. Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England. ... The date that patients will be able to access Hemlibra is expected to be announced shortly.